Investor Relations
Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Investor Relations
Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics
(As of December 31, 2021)
-
$148M
FY’21 Revenue
13% YtY Growth
(10% organic)
-
23%
YtY growth (FY'21)
Joint Preservation and Restoration
(12% organic)
-
#1
U.S. Market Share
OA Pain Management
-
$94M
Cash balance
with no debt
Current Investor Presentation
Latest Quarterly Results
Q1 2022 Earnings
Investor Day 2021
Investor Contacts
Primary IR Contact
-
Mark Namaroff
Vice President, Investor Relations, ESG, and Corporate Communications
Anika Therapeutics, Inc.
Phone: (781) 457-9287
Email: investorrelations@anika.com
-
Transfer Agent
American Stock Transfer & Trust Co.
59 Maiden Lane
New York, NY 10038
Phone: (718) 921-8261
Want Alerts? Sign up for alerts and never miss an Investor update!